Aronora, Inc. Competitors

Based in Perth, Australia, Patrys, a publicly-listed company on the Australian Securities Exchange (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys’ deoxymab platform comprises novel cell-penetrating antibodies designed to target intracellular disease mechanisms, with a focus on immune-mediated inflammatory and other high-unmet-need indications. The platform builds on technology in-licensed from Yale University and is being progressed through a comprehensive preclinical development program. Patrys’ CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive care, aged care and palliative care settings. The program is designed to leverage established safety and pharmacology data through the FDA 505(b)(2) regulatory pathway, offering a shorter and more predictable development timeline with clearly defined clinical and regulatory milestones. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation. The Company continues to advance both programs toward clinical and commercial outcomes and welcomes strategic partnership discussions across its portfolio.

Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases including brain cancers, lysosomal storage disorders, pain and others. The EPiC platform has been strongly validated in humans.

OxThera, founded in 2005 and headquartered in Stockholm, Sweden, is a biopharmaceutical company with products in late-stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes.